Kairos Pharma Successfully Completes $6.2 Million IPO
Kairos Pharma Completes Initial Public Offering
Kairos Pharma, Ltd. has made significant strides in the biopharmaceutical landscape with its recent successful initial public offering. This clinical-stage company, dedicated to developing innovative cancer therapies, raised $6.2 million through the sale of 1,550,000 shares at an offering price of $4.00 each. The common stock is now trading on the NYSE American LLC under the ticker symbol KAPA.
Utilizing Proceeds for Future Developments
The funds generated from the IPO will be instrumental in propelling the company's clinical trials forward. Specifically, they will support the Phase 1 trial for lung cancer and a Phase 2 trial for prostate cancer using Kairos Pharma's leading candidate, ENV 105. This drug aims to combat drug resistance in cancer treatments, enhancing effectiveness in patient care.
Advancing Innovative Drug Candidates
In addition to funding clinical trials, the offering will facilitate further advancements in preclinical candidates. Notably, KROS 101 is a small molecule agonist targeting the GITR ligand, which has promising potential in boosting T cell activity against cancer cells. This innovative approach reflects Kairos Pharma's commitment to revolutionizing cancer treatment methods, making it a company to watch.
Strategic Underwriting Support
Boustead Securities, LLC took the lead as the managing underwriter for this IPO, supported by co-managing underwriters EF Hutton LLC and Sutter Securities, Inc. With a robust underwriting team backing this financing, Kairos Pharma is well-positioned for its upcoming research initiatives.
Legal Counsel and Registration
Dorsey & Whitney LLP provided legal counsel to Kairos Pharma, ensuring compliance with federal regulations. The Securities and Exchange Commission declared the related registration statement on Form S-1 effective just prior to the share offerings.
About Kairos Pharma
Kairos Pharma, based in Los Angeles, is at the forefront of cancer treatment innovation. By focusing on therapies that tackle drug resistance and stimulate the immune system, the company is charting a course towards groundbreaking advancements in oncology. Their dedicated research efforts are driven by a mission to provide transformative solutions to enhance patient outcomes in cancer therapy.
Frequently Asked Questions
What type of company is Kairos Pharma?
Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company focused on developing cancer therapeutics.
How much money did Kairos Pharma raise in its IPO?
In its initial public offering, Kairos Pharma raised approximately $6.2 million.
What will the proceeds from the IPO be used for?
The proceeds will support clinical trials for lung and prostate cancer and advance preclinical drug candidates.
On which exchange is Kairos Pharma's stock traded?
Kairos Pharma's stock trades on the NYSE American LLC under the ticker symbol KAPA.
Who acted as the underwriter for the IPO?
Boustead Securities, LLC served as the lead managing underwriter, with additional support from EF Hutton LLC and Sutter Securities, Inc.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Investigation Launched for Syros Pharmaceuticals Investors
- eBay CFO Sells $1.9 Million in Stock: What to Know
- Photon Marine Secures $7 Million Grant for Green Initiatives
- Univest Securities Completes $1.2 Million Offering for FCUV
- Zero Latency VR Celebrates 100 Venues and 4 Million Players
- Clip Money Secures $2.8 Million Funding to Enhance Services
- Integral Acquisition Corp 1 Obtains $3 Million for Growth Initiatives
- Clip Money Secures $2.8 Million Investment for Growth
- Dental CAD-CAM Market Set for USD 845.8 Million Growth
- Altamira Therapeutics Launches $4 Million Share Offering
Recent Articles
- Toll Brothers Declares Quarterly Cash Dividend for Shareholders
- Weatherford International Set to Host Q3 2024 Earnings Discussion
- Allison Transmission Teams Up with LiuGong for Future Innovations
- MRC Global Prepares for Q3 2024 Earnings Call and Webcast
- Class Action Alert for Equity LifeStyle Properties Investors
- Cibus Plans Exciting Offering of Class A Common Shares Soon
- Healthy Choice Wellness Corp. Successfully Completes IPO Journey
- Lockheed Martin Chosen by NASA for Innovative Lightning Mapper
- Swvl Expands Operations with $2.6 Million Annual Contracts
- Intuitive Machines Secures NASA Contract Valued at $4.82 Billion
- Kroger and Albertsons Face Merger Challenges Amid FTC Hearing
- Snap Launches Cutting-Edge AR Glasses: Investor Insights
- Cryptocurrency Prices Surge Ahead of Federal Reserve Decision
- American Express to Host Third Quarter Earnings Call Live
- Pennsylvania's Renewed Push for Recreational Cannabis Legalization
- Publix Super Markets Charities Invests $11M to Combat Hunger
- Exciting New Housing Development Unveiled by Richmond American
- Join the Investigation: Rentokil Initial plc Shareholder Rights
- Analyzing Eli Lilly's Short Interest Trends and Market Sentiment
- Exploring Shareholder Rights in TeraWulf Inc. Case Analysis
- Understanding the Rise in Southwestern Energy's Short Interest
- Analyzing Teledyne Technologies' Short Interest Trends
- S&P 500 Soars to New Heights Amid Federal Reserve Anticipations
- Join the TeraWulf Inc. Investigation with Leading Law Firm
- Weyerhaeuser and Nature Conservancy Team Up for Climate Action
- Oracle Enhances Veteran Care with New Code Integration
- Amtech Systems Eliminates $3.8 Million Debt, Signals Future Strategy
- Explore the Newest Living Options at Foxhaven Community
- Significant Changes at 23andMe: Directors Depart Amidst Conflict
- Context Therapeutics Expands Share Authorization to 200 Million
- Charles Zhang Achieves Top Spot as Independent Advisor of 2024
- Virpax Pharmaceuticals Board Faces Change as Dr. Singh Resigns
- Exciting New Meal Deals and Menu Highlights from Taco Cabana
- Stifel Sets Bullish $238 Price Target for Penumbra's Growth
- Perrigo Completes $715 Million Senior Notes Offering Successfully
- Stifel's Cautious Outlook for Inari Medical Amidst Market Changes
- Warner Music Group Enhances Financial Flexibility with Loan Amendments
- Jones Trading's Hold Rating for Beam Therapeutics Explained
- Recent Share Disposals Highlight IBEX Ltd’s Market Dynamics
- Bovespa Declines as Key Sectors Struggle in Trading Session
- Canadian Market Overview: S&P/TSX Composite Sees Minor Decline
- Stock Market Round-Up: Trends from Major U.S. Indices
- Keen Shuja Makes Strategic Share Sales in IBEX Ltd
- Quanterix Director Boosts Confidence with $624K Stock Purchase
- Inside JFrog: Yoav Landman's Share Sale and Company Insights
- Globus Medical Director's Significant Share Transactions Revealed
- RBC Bearings CEO Executes Major Stock Sale and Options Exercise
- Exploring Top Dividend Stocks for Income Investors Today
- Yellow Corp Faces Major Loss as Court Rules Against It
- Analyzing Upcoming Federal Reserve Rate Cuts and Their Impact